ClinicalTrials.gg
Drug

Miglustat clinical trials

Also written Zavesca, OGT 918 and Butyldeoxynojirimycin.

studies test it
21
open now
1
in phase 3
6
first study started
2002

How each study uses miglustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the miglustat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
31 Jul 2003 · ZAVESCA · NDA 021348 (FDA, Drugs@FDA)
European Union
20 Nov 2002 · Zavesca · EMEA/H/C/000435 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Miglustat
14
AT2221
2

Brand

Zavesca
8

Development codes

OGT 918
3

Other names

Butyldeoxynojirimycin
2

Studies by the year they started

19 studies that test it; most in 2002 (3)

Studies that test miglustat, by start year
YearStudies
20023
20042
20051
20061
20071
20082
20091
20152
20161
20181
20191
20201
20211
20231

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
8
Phase 3
6
Phase 4
3
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 12

Actelion (5) · Amicus Therapeutics (2) · National Taiwan University Hospital (2) · G D Searle (2) · IRCCS Fondazione Stella Maris (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1) · National Eye Institute (NEI) (1) · The Hospital for Sick Children (1)

Often tested with

Tested in the same studies.

Cipaglucosidase alfa (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test miglustat, phase 3 first.

Studies

Open first, then newest update. How each study uses miglustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 21

See all 21 studies that test miglustat →

Given beside what is tested · 1 — miglustat is usual care or a partner of the new treatment

Codes

What other systems call miglustat · ClinicalTrials.gg INT003439

  • MeSH (NLM) C059896miglustatConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) ADN3S497AZMIGLUSTATConfirmed FDA, NLM, Wikidata
  • RxNorm 402316Confirmed FDA, Wikidata
  • Wikidata Q425911miglustatConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1222MiglustatOne source FDA
  • DrugBank DB00419One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.